22 research outputs found

    Dynamic Business Models: a Proposed Framework to Overcome the Death Valley

    No full text
    The ex ante definition of business model offers the possibility to create a static picture of “how” the company is able to generate value in a given moment. But is this business model able to generate value over time? The time factor of the value proposition life cycle is not usually taken into account. This paper, starting from the lean canvas model (Maurya 2012), proposes a framework able to consider the temporal factor and, coming from Rogers’s innovation diffusion theory (Die Diffusion von Innovationen in der Telekommunikation, 17, 25–38, Rogers 1995), to evolve the business model from a single picture to a set of pictures representing the many phases of the value proposition life cycle. A local context analysis was conducted, interviewing 10 CEOs of University of Salento start-ups, and the framework’s tool kit was developed: application methodology, questionnaire, and glossary. To validate the tools and methodology, a real business case was considered. Using the framework proposed in the business model definition would allow managers of start-ups to identify several marketing strategies, channels, and key metrics dedicated to each customer category

    Angelman syndrome (AS, MIM 105830)

    No full text
    Angelman syndrome (AS) is a distinct neurogenetic syndrome, first described in 1965. The phenotype is well known in infancy and adulthood, but the clinical features may change with age. The main clinical characteristics include severe mental retardation, epileptic seizures and EEG abnormalilties, neurological problems and distinct facial dysmorphic features. Behavioural problems such as hyperactivity and sleeping problems are reported, although these patients present mostly a happy personality with periods of inappropriate laughter. Different underlying genetic mechanisms may cause AS, with deletion of chromosome 15 as the most frequent cause. Other genetic mechanisms such as paternal uniparental disomy, imprinting defect and mutation in the UBE3A gene are present in smaller groups of patients with AS. As the recurrence risk can be up to 50%, the clinical diagnosis of AS should be confirmed by laboratory tesing, and genetic counselling should be provided. Treatment of seizures, physical therapy or other intervention strategies are helpful to ameliorate the symptoms
    corecore